SCHEMBL987931

SCHEMBL987931

O=C(O)c1ccc(CNC(=O)c2cccc3ccn(Cc4ccc(Cl)cc4)c23)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 10/20 0.54
PTGDR Q13258 9/20 0.54
PTGER2 P43116 2/20 0.48
TBXA2R P21731 1/20 0.48
PTGER1 P34995 1/20 0.48
PTGFR P43088 1/20 0.48
PTGER3 P43115 1/20 0.48
EPHX2 P34913 2/20 0.46
NR1H4 Q96RI1 1/20 0.46
PPARG P37231 1/20 0.45
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44
NLRP1 Q9C000 1/20 0.44
KLK1 P06870 2/20 0.43
KLKB1 P03952 1/20 0.43
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12948753 0.91 PTGER4 (0.54) PTGER4PTGDRPTGER2TBXA2RPTGER1
SCHEMBL12585333 0.91 PTGER4 (0.52) PTGER4PTGDRPTGER2TBXA2RPTGER1
SCHEMBL12585427 0.91 PTGER4 (0.54) PTGER4PTGDRPTGER2TBXA2RPTGER1
SCHEMBL12585417 0.88 PTGER4 (0.52) PTGER4PTGDRPTGER2TBXA2RPTGER1
SCHEMBL10085256 0.88 PTGER4 (0.59) PTGER4PTGDRPTGER2TBXA2RPTGER1
SCHEMBL12584021 0.81 PTGER4 (0.47) PTGER4PTGDRPTGER2TBXA2RPTGER1
SCHEMBL12583951 0.81 PTGER4 (0.46) PTGER4PTGDRPTGER2TBXA2RPTGER1
SCHEMBL12583962 0.81 PTGER4 (0.46) PTGER4PTGDRPTGER2PPARGLMNA
SCHEMBL12585300 0.80 PTGER4 (0.68) PTGER4PTGDRPTGER2TBXA2RPTGER1
SCHEMBL12900500 0.80 PTGER4 (0.47) PTGER4PTGDRPTGER2TBXA2RPTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2565191-B1 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy ASTELLAS PHARMA INC (JP) 2014-10-08 EP disclosed
US-8598355-B2 Amide compound ASTELLAS PHARMA INC. (JP) 2013-12-03 US disclosed
EP-2565191-A1 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy Astellas Pharma Inc. (JP) 2013-03-06 EP disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
EP-2277858-A1 AMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-01-26 EP disclosed
EP-2277858-A1 AMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-01-26 EP disclosed
WO-2009139373-A1 AMIDE COMPOUND アステラス製薬株式会社 (JP) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144153-A1 AMIDE COMPOUND PTGER4, PTGER1, PTGER2 PTGER4 1/4885PTGDR 13/4885PTGER2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.